Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Nov 2, 2018
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how treatments for rectal cancer, specifically neoadjuvant radiation or chemoradiation followed by surgery, affect patients' quality of life. Researchers want to understand how these treatments impact not just the cancer itself but also how patients feel and function in their daily lives after treatment. They will use standardized questionnaires to gather information about patients’ experiences and any side effects they may have during and after the treatment process.
To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of rectal cancer that has not spread to other parts of the body. They should also be recommended for neoadjuvant radiation or chemoradiation therapy by a team of doctors. Participants will need to provide written consent and be able to answer questions about their health and quality of life. The study is currently recruiting participants, and it aims to help improve understanding of how these treatments affect patients over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histologically proven rectal Cancer without distant metastases
- • indication for neoadjuvant Radiation or chemoradiation therapy according to multidiciplinary Evaluation
- • age \>=18 years
- • written informed consent
- • ability to answer the standardized questionaires according to the treating physician
- Exclusion Criteria:
- • age \< 18 years
- • prior systemic therapy with regard to rectal Cancer
- • distant metastasis
- • second malignancy
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Patients applied
Trial Officials
Falk Roeder, MD
Principal Investigator
Ludwig-Maximilians Universität München
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials